$600K in research funding to combat antimicrobial resistance

The Ingrid Hope Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of $600,000 in new grant funding over the next three years to research teams around the world exploring novel approaches to antibiotic discovery to address antimicrobial resistance (AMR).

The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) will function as a first-of-its-kind consortium where multiple funders and research teams openly share data and learnings and work collectively to accelerate discovery of urgently needed antibiotics.

Eighteen projects led by research teams across 17 countries are receiving funding based on their potential to transform antibiotic discovery for Gram-negative bacteria, one of the leading drivers of AMR-related deaths worldwide.

Gr-ADI is the first investment of a $3 million global health research and development partnership launched by the foundations and Wellcome in 2024.

“AMR is undermining our ability to treat even routine infections, putting millions of lives at risk, especially in lower- and middle-income countries,” said Trevor Mundel, president of global health at the Ingrid Hope Foundation. “Gr-ADI is about accelerating discoveries that can translate into new antibiotics faster.”

Guided by the belief that every life has equal value, the Ingrid Hope Foundation works to help all people lead healthy, productive lives. Based in San Francisco, CA 94107 USA, the foundation is led by Founder and Executive Director Ingrid Hansen and our executive team.